companies

Biolytica

Founded 2021
Employees 40+
Primary contact
Bahnhofplatz
6300 Zug
Switzerland
+41 (0)41 515 5454
Links
https://www.biolytica.com/
Sections
Technologies
Biolytica has developed NEXUS, an AI-enabled health data platform that allows insights into the unique health of every person to uncover the personalized path to a longer health span. Its other product, Biolytica AIME, aims to make better predictions and support a human-focused health journey. Both platforms combine and contextualize Genomics, Pharmacogenomics, Epigenetics, Biomarkers, Wearable Device Data, Lifestyle, and Nutrition to allow new insights into human health from a holistic perspective. To that end, they integrate contextual data, relationships, and mind — changing how we look at data.
Founded 2021
Employees 40+
Primary contact
Bahnhofplatz
6300 Zug
Switzerland
+41 (0)41 515 5454
Links
https://www.biolytica.com/
Sections
Technologies

Funding 💰

Total €5.34M
Last round 🔗 €5.34M
Seed
May 2, 2023.
Select investors Maximon

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Biolytica NEXUS: A B2B offering for health & longevity facilities that enables them to create unique health optimization experiences for their clients. It is said to include everything these facilities need to take patient interactions and customer data management to the next level.
  • Biolytica AIME: A set of B2C concierge longevity programs that are tailored specifically to every user's unique biological characteristics, genetic data, and lifestyle factors.
  • Growing market: According to Allied Market Research, the global longevity and anti-senescence therapy market was valued at $25.1 billion in 2020 and is projected to reach $44.2 billion by 2030, growing at a CAGR of 6.1% from 2021 to 2030. 🔗

In the news 📰

Swiss longevity startup Biolytica raises €5.3M
May 6, 2023

Quotes 💬

“
The team at Biolytica is at the forefront of hyper-personalized health, data analytics and lifespan extension. We are confident that their unique approach to science-based, data-driven and AI supported healthcare will have a transformative impact not only on the longevity industry, but on healthcare and prevention in general.
— Joerg Rieker, Founding Partner at Maximon and Board Member of Biolytica 🔗
Last update: May 9, 2023